In addition to its benefits for atherosclerotic cardiovascular diseases, our research suggests that treatment with SGLT-2 inhibitors such as dapagliflozin may reduce the risk, and the progression of small AAAs. The gene discussed is SLC5A2; the disease is achalasia-alacrima syndrome.